Normobaric Hyperoxia Combined With Endovascular Treatment in Acute Ischemic Stroke (OPENS-2)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The current endovascular treatment has increased the recanalization rate to more than 90%.
Even so, the prognosis rate of stroke is still less than 50%. Our previous research confirmed
that the neuroprotective effect of Normobaric Hyperoxia (NBO) from multiple perspectives.
However, the clinical study on NBO was not satisfactory, which might be due to the absence of
vascular recanalization therapy. Therefore, The investigators conducted this RCT study to
further explore the Efficacy and safety of NBO combined with endovascular treatment in
patients with acute ischemic stroke.
Phase:
Phase 2
Details
Lead Sponsor:
Capital Medical University
Collaborators:
Beijing Fengtai You'anmen Hospital Henan Provincial People's Hospital Jiujiang University Affiliated Hospital Second Affiliated Hospital of Soochow University Shengli Oilfield Hospital Tianjin Huanhu Hospital